Nosopharm Signs an Agreement with Evotec to Accelerate the Development of Antibiotics

Shots:

• Nosopharm and Evotec collaborated to advance Nosopharm’s NOSO-502 to clinical stage and to develop second-generation Odilorhabdin (ODLs) for hospital-acquired pneumonia and ventilation-associated pneumonia (HAP/VAP), under the name NOSO-2G
• The collaboration initially focuses on Chemistry, Manufacturing and Control (CMC) and Clinical Trial Application (CTA)-enabling and filing activities regarding NOSO-502 for the onset of P-I study of NOSO-502 for the treatment of cUTI & cIAI
• NOSO-502 belongs to the class of ODLs inhibiting bacterial ribosomes and is intended to treat nosocomial infections by Enterobacteriaceae with its expected CTA-filing and initiation of clinical study in 2021

Click here to read full press release/ article | Ref: Nosopharm | Image: Evotec